Cognitive deficits among people with schizophrenia and prediabetes or diabetes.

John, AP; Mya, T; Haywood, D

Cognitive deficits among people with schizophrenia and prediabetes or diabetes.

John, AP Mya, T Haywood, D

Permalink

Publisher:: WILEY
Publication Type:: Journal Article
Citation:: Acta Psychiatr Scand, 2024, 149, (1), pp. 65-76
Issue Date:: 2024-01

Open Access

Copyright Clearance Process

Recently Added
In Progress
Open Access

This item is open access.

Adobe PDF

Download full textAdobe PDF (1.02 MB)

View on publisher's site

View statistics

Full metadata record

Field	Value	Language
dc.contributor.author	John, AP
dc.contributor.author	Mya, T
dc.contributor.author	Haywood, D https://orcid.org/0000-0002-9317-4135
dc.date.accessioned	2024-01-11T01:15:29Z
dc.date.available	2023-10-13
dc.date.available	2024-01-11T01:15:29Z
dc.date.issued	2024-01
dc.identifier.citation	Acta Psychiatr Scand, 2024, 149, (1), pp. 65-76
dc.identifier.issn	0001-690X
dc.identifier.issn	1600-0447
dc.identifier.uri	http://hdl.handle.net/10453/174263
dc.description.abstract	INTRODUCTION: Both type 2 diabetes mellitus (T2DM) and schizophrenia are known to be associated with cognitive deficits. The impact of the comorbidities of T2DM or prediabetes (PD) on cognition among people with schizophrenia has been poorly researched. We evaluated the cognitive functioning of patients with schizophrenia and PD or T2DM and compared them to patients with schizophrenia with normal blood sugar. METHODS: We retrospectively collated data on cognition, fasting blood glucose (FBG), lipids and other selected demographic and clinical variables of 171 patients with schizophrenia and 16 patients with schizoaffective disorder who were admitted to an inpatient rehabilitation facility in Western Australia from 2011 to 2018. The Brief Assessment of Cognition in Schizophrenia (BACS) was used to evaluate cognitive functioning. Parametric and non-parametric analyses were used to examine the study's aims. RESULTS: Sixty-six percent of the patients had normal blood sugar, 25% had PD and 9% had T2DM. The BACS composite score revealed an increasing gradient of cognitive deficits, ranging from mild to severe, between the normal, PD and T2DM groups, respectively. The T2DM group had a significantly lower composite score compared with the PD (p = 0.026) and normal groups (p < 0.001). On the BACS subtests, the scores of T2DM and PD patients were similar except for the token motor task, in which the T2DM group had significantly lower scores (p < 0.001). The T2DM group also had lower scores on the subtests of BACS, except memory tests, compared with those with normal blood sugar. There was no significant difference in the composite and subtest cognitive scores between the PD and normal groups. CONCLUSIONS: Our study revealed more pronounced cognitive deficits among patients with schizophrenia and dysglycaemia, particularly those with T2DM, compared with those with schizophrenia with normal blood sugar.
dc.format	Print-Electronic
dc.language	eng
dc.publisher	WILEY
dc.relation.ispartof	Acta Psychiatr Scand
dc.relation.isbasedon	10.1111/acps.13627
dc.rights	info:eu-repo/semantics/openAccess
dc.subject	11 Medical and Health Sciences, 17 Psychology and Cognitive Sciences
dc.subject.classification	Psychiatry
dc.subject.classification	32 Biomedical and clinical sciences
dc.subject.classification	42 Health sciences
dc.subject.classification	52 Psychology
dc.subject.mesh	Humans
dc.subject.mesh	Schizophrenia
dc.subject.mesh	Prediabetic State
dc.subject.mesh	Diabetes Mellitus, Type 2
dc.subject.mesh	Blood Glucose
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Neuropsychological Tests
dc.subject.mesh	Cognitive Dysfunction
dc.subject.mesh	Cognition
dc.subject.mesh	Humans
dc.subject.mesh	Diabetes Mellitus, Type 2
dc.subject.mesh	Prediabetic State
dc.subject.mesh	Blood Glucose
dc.subject.mesh	Retrospective Studies
dc.subject.mesh	Cognition
dc.subject.mesh	Schizophrenia
dc.subject.mesh	Neuropsychological Tests
dc.subject.mesh	Cognitive Dysfunction
dc.title	Cognitive deficits among people with schizophrenia and prediabetes or diabetes.
dc.type	Journal Article
utslib.citation.volume	149
utslib.location.activity	United States
utslib.for	11 Medical and Health Sciences
utslib.for	17 Psychology and Cognitive Sciences
pubs.organisational-group	/University of Technology Sydney
pubs.organisational-group	/University of Technology Sydney/Faculty of Health
utslib.copyright.status	open_access	*
dc.date.updated	2024-01-11T01:15:28Z
pubs.issue	1
pubs.publication-status	Published
pubs.volume	149
utslib.citation.issue	1

Abstract:

INTRODUCTION: Both type 2 diabetes mellitus (T2DM) and schizophrenia are known to be associated with cognitive deficits. The impact of the comorbidities of T2DM or prediabetes (PD) on cognition among people with schizophrenia has been poorly researched. We evaluated the cognitive functioning of patients with schizophrenia and PD or T2DM and compared them to patients with schizophrenia with normal blood sugar. METHODS: We retrospectively collated data on cognition, fasting blood glucose (FBG), lipids and other selected demographic and clinical variables of 171 patients with schizophrenia and 16 patients with schizoaffective disorder who were admitted to an inpatient rehabilitation facility in Western Australia from 2011 to 2018. The Brief Assessment of Cognition in Schizophrenia (BACS) was used to evaluate cognitive functioning. Parametric and non-parametric analyses were used to examine the study's aims. RESULTS: Sixty-six percent of the patients had normal blood sugar, 25% had PD and 9% had T2DM. The BACS composite score revealed an increasing gradient of cognitive deficits, ranging from mild to severe, between the normal, PD and T2DM groups, respectively. The T2DM group had a significantly lower composite score compared with the PD (p = 0.026) and normal groups (p < 0.001). On the BACS subtests, the scores of T2DM and PD patients were similar except for the token motor task, in which the T2DM group had significantly lower scores (p < 0.001). The T2DM group also had lower scores on the subtests of BACS, except memory tests, compared with those with normal blood sugar. There was no significant difference in the composite and subtest cognitive scores between the PD and normal groups. CONCLUSIONS: Our study revealed more pronounced cognitive deficits among patients with schizophrenia and dysglycaemia, particularly those with T2DM, compared with those with schizophrenia with normal blood sugar.

Please use this identifier to cite or link to this item:

http://hdl.handle.net/10453/174263